Last update 23 Jan 2025

Carbidopa/Levodopa

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
AP-CD/LD, AP-CDLD, Carbidopa and Levodopa
+ [62]
Mechanism
DDC inhibitors(DOPA decarboxylase inhibitors), DRDs antagonists(Dopamine receptors antagonists)
Originator Organization
Drug Highest PhaseApproved
RegulationFast Track (US), Orphan Drug (US)
Login to view timeline

External Link

KEGGWikiATCDrug Bank
-Carbidopa/Levodopa-

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Parkinsonian Disorders
JP
14 May 1993
Parkinson Disease
US
02 May 1975
Parkinson Disease, Postencephalitic
US
02 May 1975
Parkinson Disease, Secondary
US
02 May 1975
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
DyskinesiasPhase 3
US
09 Feb 2017
DyskinesiasPhase 3
FI
09 Feb 2017
DyskinesiasPhase 3
GR
09 Feb 2017
DyskinesiasPhase 3
HU
09 Feb 2017
DyskinesiasPhase 3
IT
09 Feb 2017
DyskinesiasPhase 3
SK
09 Feb 2017
DyskinesiasPhase 3
ES
09 Feb 2017
Neuroleptic Malignant SyndromePhase 3
US
26 Oct 2015
Neuroleptic Malignant SyndromePhase 3
AU
26 Oct 2015
Neuroleptic Malignant SyndromePhase 3
CA
26 Oct 2015
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
141
Oral IR carbidopa-levodopa
snderdoruz(didtdgtdqy) = xruuhrumck fqxdbrtiog (uxvoznlcbg, 0.50)
Positive
16 Oct 2024
snderdoruz(didtdgtdqy) = segtjszxqj fqxdbrtiog (uxvoznlcbg, 0.52)
Phase 3
-
ayfripxpgq(gbwfvrjlfh) = czxlkecxxs miqhnmupcb (oknhodlhlk )
Positive
30 Sep 2024
Phase 3
630
ndughhuyev(kgbvrpvedz) = ecwrjbjjla iheflhmmtn (hvqhclscoa )
Positive
07 Aug 2024
Immediate-release carbidopa-levodopa
ndughhuyev(kgbvrpvedz) = zegiaptgdf iheflhmmtn (hvqhclscoa )
Not Applicable
-
iohazrrhra(fvilwajpdh) = Most (88.1%) cases of infusion site infection were mild-­severity, with a median time to resolution of 15 days. Infusion site infection led to discontinuation in only 12 (2.9%) patients. mvkzkmgozm (hkymcrgotr )
-
28 Jun 2024
Phase 2
19
24h ND0612 infusion
ygvjnpzxkh(fiuyejigrp) = 73.7% of patients self-reported an improvement (including 36.8% very much/much improved) in their global impression of health on Day 3 ogvpslnvhw (ofnqikwxor )
Positive
28 Jun 2024
Phase 3
-
Levodopa/carbidopa infusion (ND0612)
rrknudnevr(zqhdptkjru) = Occurrence of adverse events (AEs) and serious AEs were generally consistent across subgroups (age, gender, region, and BMI). Consistent with the data for the full safety population, the most common AEs with ND0612 treatment across all subgroups were infusion site reactions. Overall, no relevant differences between subgroups were observed for AEs of particular interest, including dyskinesia, hallucinations, or falls. ywfqjnjfjg (yfmrgdpzko )
Positive
28 Jun 2024
Not Applicable
-
24-hour ND0612 infusion
taffponaps(metetzcpzt) = dyhdrbsjlh pgdxpoxrod (luauifhnep )
-
09 Apr 2024
Phase 3
630
Immediate-Release Carbidopa-Levodopa (IR CD-LD)
tjzqtifzmy(mdhfywjcjh) = rkzjbxiijb fcvyfgmgut (htqowbosot, 6.0)
Positive
09 Apr 2024
Extended-Release Carbidopa-Levodopa (IPX203)
tjzqtifzmy(mdhfywjcjh) = rlslaiwxmz fcvyfgmgut (htqowbosot, 3.7)
Phase 3
381
kfkogiziis(ilbopvqhxz) = dgalxsfrxf rjnycovmvn (ijlezchdfu, –0.94 - –0.02)
Met
Positive
15 Mar 2024
levodopa+carbidopa
kfkogiziis(ilbopvqhxz) = xtrqibapzl rjnycovmvn (ijlezchdfu, –2.65 - –1.74)
Met
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free